The protein-protein interaction between the subunits of the heterodimeric transcription factor CBF, core binding factor beta (CBFb) and Runx1 (CBFa), plays a critical role in hematopoiesis. Chromosomal rearrangements that target the core-binding factor genes are some of the most common mutations in leukemia. RUNX1 (AML1) is disrupted by the t(8;21)(q22;q22), t(12;21)(p13;q22), t(3;21)(q26;q22), t(16;21)(q24;q22), t(1;21)(p36;q22), t(5;21)(q13;q22), t(12;21)(q24;q22), t(14;21)(q22;q22), t(15;21)(q22;q22), and t(17;21)(q11.2;q22), all of which are associated with myeloid and lymphocytic leukemia. The gene coding for the CBFb subunit (CBFB) is also the target of a common chromosomal translocation, inv(16). The role of CBFb binding for the (dys)function of AML1-ETO, product of the t(8;21) mutation, was recently examined. The introduction of point mutations into the Runt domain in AML1-ETO which abrogates CBFb binding 400-fold results in loss of the ability to immortalize lin- BM cells as well as a loss of leukemogenesis in a mouse model of AML1-ETO leukemia. These results validate this protein-protein interaction as an appropriate target for the development of a small molecule inhibitor which may have therapeutic usefulness for appropriate forms of leukemia. The purpose of this assay to use HTS to identify inhibitors of the protein-protein interaction between the RUNX1 Runt domain and CBFb. This assay is a counterscreen for the primary screening assay.  This is accomplished by using a time resolved fluorescence resonance energy transfer (TR-FRET) assay.  If an inhibitor is present, binding will not occur and the TR-FRET signal will be abated. Assay materials: 1) Venus-CBFb, His-CBFa and His-CBFb were provided by Dr. John Bushweller (University of Virginia Charlottesville, Charlottesville VA). 2) Tb-anti-His (Invitrogen) uHTS protocol: 1) The protein complex (PC); 100nM His-CBFa, 100nM Venus-CBFb, 1nM Tb-anti-His in 50mM Tris pH7.5, 100mM KCl, 10mM K2SO4, 2mM Mg2SO4, and 0.01% BSA is incubated in the dark at room temperature. 2) After 1 hour 4ul of PC is dispensed into columns 3 through 48 of a white 1536 well plate 3) 4ul of positive control (PC + 1.25uM His-CBFb) is added to the wells in columns 1 and 2. 4) 40nl of 100% DMSO is added to wells in columns 1 through 4, while 40nl of 2mM compounds in 100% DMSO is added to wells in columnsd 5 through 48.  Final compound concentration is 20uM, final DMSO concentration is 1%. 5) The plate is incubated for 1 hr at room temperature protected from light. 6) After 1 hour the plate is read on a BMG Pherastar using a Lanthascreen filter set: 337ex, 520em and 490em 7) Raw values are the ratio of 520/490 signals * 10,000.
bao:BAO_0001077 "1434_1" ; # "is alternate confirmatory assay of" -> "1434_1"
bao:BAO_0000812 "1639" ; # "has summary assay" -> "1639"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0001078 bao:BAO_0001096 ; # "has orthogonal assay technology" -> "orthogonal assay technology"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000223 ; # "has assay format" -> "protein complex format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BAO_0000399 bao:BAO_0000282 ; # "has transcription factor" -> "transcription factor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_00020101 ; # "is bioassay type of" -> "protein-protein interaction assay"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "His6-Runx1/Venus-CBFb" ; # "protein-protein" -> "His6-Runx1/Venus-CBFb"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000004 ; # "has detection method" -> "time resolved fluorescence resonance energy transfer"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "To identify inhibitors of the protein-protein interaction between the RUNX1 Runt domain and CBFb." ; # "screening campaign name" -> "To identify inhibitors of the protein-protein interaction between the RUNX1 Runt domain and CBFb."
bao:BAO_0002853 "Identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a time resolved fluorescence resonance energy transfer (TR-FRET) assay." ; # "has assay title" -> "Identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a time resolved fluorescence resonance energy transfer (TR-FRET) assay."
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "1 hour" ; # "has incubation time value" -> "1 hour"
bao:BA0_0090012 "\"Protein Complex Soln (100 nanomolar His-CBFa, 100 nanomolar Venus-CBFb, 1 nanomolar Tb-anti-His) + 1.25 millimolar His-CBFb\"" ; # "has participant" -> ""Protein Complex Soln (100 nanomolar His-CBFa, 100 nanomolar Venus-CBFb, 1 nanomolar Tb-anti-His) + 1.25 millimolar His-CBFb""
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "John Bushweller" ; # "material entity assay provider" -> "John Bushweller" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000694 ; # "has participant" -> "Tris" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 "Core-binding factor subunit beta isoform 1" ; # "has participant" -> "Core-binding factor subunit beta isoform 1"
bao:BA0_0090012 "Runt-related transcription factor 1 isoform AML-1C" ; # "has participant" -> "Runt-related transcription factor 1 isoform AML-1C"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q13951-1" ; # "uniprot ID" -> "Q13951-1"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q01196-3" ; # "uniprot ID" -> "Q01196-3"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002662 bao:BAO_0000644 ; # "has quality" -> "truncated"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0000502 "\"Tb-anti-His, Invitrogen\"" ; # "antibody" -> ""Tb-anti-His, Invitrogen""
bao:BA0_0090012 "Venus" ; # "has participant" -> "Venus"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000705 ; # "uses detection instrument" -> "PHERAstar Plus"
bao:BAO_0000737 bao:BAO_0000863 ; # "has manufacturer" -> "BMG Labtech" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "337 nanometer" ; # "has excitation wavelength value" -> "337 nanometer"
bao:BAO_0002918 "490 nanometer" ; # "has emission wavelength value" -> "490 nanometer"
bao:BAO_0002918 "520 nanometer" ; # "has emission wavelength value" -> "520 nanometer"
bao:BAO_0000337 bao:BAO_0000201 ; # "has percent response" -> "percent inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5" ; # "PubChem TID" -> "5"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "20" ; # "has concentration value" -> "20"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie" ; # "Annotated by" -> "kunie"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
